Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
The guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend adding omalizumab to the treatment of patients with uncontrolled disease despite four-fold doses of second-generation antihistamines (AH). On the contrary, some studies revealed that omalizumab was effective without co...
| Autores: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repositorio: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:i3pt.fundanetsuite.com:p1497 |
| Acceso en línea: | https://i3pt.portalinvestigacion.com/publicaciones/1497 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143321927&doi=10.1684%2fejd.2022.4334&partnerID=40&md5=49f05c4d74a4838285b4fa1b3b643571 |
| Access Level: | acceso abierto |
| Palabra clave: | antihistamines, chronic spontaneous urticaria, chronic urticaria |
| Sumario: | The guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend adding omalizumab to the treatment of patients with uncontrolled disease despite four-fold doses of second-generation antihistamines (AH). On the contrary, some studies revealed that omalizumab was effective without concomitant AH and several authors suggest tapering off AH when CSU is controlled with omalizumab. |
|---|